Beactica, the Swedish fragment-based drug discovery company, today announced an important move to address the need for increased data quality and higher capacity in understanding molecular interactions. Growing customer demand for solutions to ever more complex research challenges has led Beactica to invest in the world’s most sophisticated SPR biosensor to date, the Biacore 4000. The instrument will enable Beactica to offer more advanced experimental designs and a deeper interpretation of interaction analysis data so that stronger therapeutic candidates can be developed.
“Our customers are amongst the most progressive pharmaceutical companies in the world; to deliver results that continue to impress them, we need to combine the best scientist in our field with the most advanced equipment”, says Per Källblad, Beactica’s CEO. “There is a real sense of excitement in our labs about the potential of the Biacore 4000, both for our own projects and those of our customers”.
The instrument enables improved insights in kinetics and interaction mechanisms. “It’s like the difference between using a magnifying glass and a microscope” Per Källblad remarks, ”we’ll be able to see more and therefore understand more”. In particular it will further Beactica’s ability to successfully address conformationally flexible targets such as kinases and ion channels. Both these protein classes are of significant importance for human health and need to be better understood to successfully develop next-generation therapeutics.
Helena Danielson, Beactica’s CSO, comments that the capacity of the instrument will enable Beactica to expand the range and complexity of projects that it undertakes. “The possibilities of using more flexible and efficient experimental designs will enrich the information content of the resulting data. This means that our customers can advance their programmes faster and in a more intelligent manner”.
Beactica will take delivery of the Biacore 4000 later this month; the Company also upgrades its existing instrumentation to higher specifications.
For additional information please contact Dr Per Källblad, Beactica CEO, +46 18 560880.
Beactica AB is a specialist drug discovery company, utilising its proprietary methodologies to evaluate the interaction of molecules in order to generate novel therapeutics. The Company offers expertise and services in the area of SPR biosensor-based small molecule interaction analysis and partnerships for fragment-based lead generation using its proprietary Sprint™ platform. Founded in 2006 based on research carried out at Uppsala University and first-hand experience from the drug discovery industry, Beactica has established a robust reputation as the leader in SPR-based small molecule drug discovery. As well as providing services and building collaborations with external companies, Beactica is progressing its own drug discovery programmes. For more information, please visit www.beactica.com.